.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The INCREASE trial evaluated inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease. The randomized, placebo-controlled study demonstrated an improvement in exercise capacity measured by the six-minute walk distance and reduced the risk of clinical worsening compared with placebo. The findings are important because pulmonary hypertension in ILD can add a major burden of symptoms and functional limitation, yet treatment options historically have been limited. The study supports the idea that pulmonary vascular disease should be actively considered when symptoms or functional decline appear disproportionate to the underlying parenchymal lung disease. This is closely aligned with the NAPCON session on screening for pulmonary hypertension in progressive ILD. For HCPs, the message is to recognize when pulmonary vascular evaluation may add diagnostic and therapeutic value rather than assuming every decline is caused by worsening fibrosis alone. The treatment studied here is specific to pulmonary hypertension associated with ILD and should not be generalized to all forms of pulmonary hypertension. The paper is especially useful for multidisciplinary care involving ILD specialists, pulmonary hypertension teams and rehabilitation services.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The INCREASE trial evaluated inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease. The randomized, placebo-controlled study demonstrated an improvement in exercise capacity measured by the six-minute walk distance and reduced the risk of clinical worsening compared with placebo. The findings are important because pulmonary hypertension in ILD can add a major burden of symptoms and functional limitation, yet treatment options historically have been limited. The study supports the idea that pulmonary vascular disease should be actively considered when symptoms or functional decline appear disproportionate to the underlying parenchymal lung disease. This is closely aligned with the NAPCON session on screening for pulmonary hypertension in progressive ILD. For HCPs, the message is to recognize when pulmonary vascular evaluation may add diagnostic and therapeutic value rather than assuming every decline is caused by worsening fibrosis alone. The treatment studied here is specific to pulmonary hypertension associated with ILD and should not be generalized to all forms of pulmonary hypertension. The paper is especially useful for multidisciplinary care involving ILD specialists, pulmonary hypertension teams and rehabilitation services.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
